UmeshJadhavChaudhariMD

PubMed

• 139 citations
  Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab: Pooled Data From Randomized Trials
  Jennifer G. Robinson, Robert S. Rosenson, Michel Farnier, Umesh Chaudhari, William J. Sasiela, Laurence Merlet, Kathryn Miller, John J.P. Kastelein> ;Journal of the American College of Cardiology. 2017 Feb 7
• 46 citations
  Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholeste...
  John J.P. Kastelein, G. Kees Hovingh, Gisle Langslet, Marie T. Baccara-Dinet, Daniel A. Gipe, Umesh Chaudhari, Jian Zhao, Pascal Minini, Michel Farnier> ;Journal of Clinical Lipidology. 2017 Jan 1
• 269 citations
  Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin the...
  Dean J. Kereiakes, Jennifer G. Robinson, Christopher P. Cannon, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari, Helen M. Colhoun> ;American Heart Journal. 2015 Jun 1
• 301 citations
  Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ...
  Christopher P. Cannon, Bertrand Cariou, Dirk J. Blom, James M. McKenney, Christelle Lorenzato, Robert Pordy, Umesh Chaudhari, Helen M. Colhoun> ;European Heart Journal. 2015 May 14
• Join now to see all

Abstracts/Posters

• Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US
  Umesh Chaudhari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I N...
  Umesh Chaudhari, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019